Email: nbansback_at_cheos.ubc.ca

Phone: (1) 604-682-2344 (63561)

Health Economist, Centre for Health Evaluation and Outcome Sciences, Vancouver, Canada

PhD student, Health Economics and Decision Sciences, University of Sheffield, UK

ongoing    PhD Health Economics (University of Sheffield) expected completion 2010

2004        MSc Health Services Research (University of Sheffield)

2000        BSc Mathematics (University of Sheffield)

Co-investigator 

• 2010-current. Preparatory study for the re-evaluation of the EQ-5D tariff. (PI Aki Tsuchiya). Medical Research Council ₤303,328 (approx $500,000)
• 2010-current. Multi-country pilot study on the relationship between DCE and TTO derived EQ-5D-5L health-state values (PI Paul Krabbe) EuroQol group. €217,000 (€45,000 for Canada).
• 2010-current. Valuing health status of general population: Development of a Canadian preference-based scoring system for the new 5-level EQ-5D (PI Feng Xie, Jeff Johnson). Canadian Institute for Health Research. $100,000
• 2007-2008. Role of statins in prevention and management of rheumatoid arthritis (PI Hyon Choi). Canadian Institute for Health Research. $197,000
• 2007-2009. A comparison of condition specific versus generic health state utilities in persons with rheumatoid arthritis (PI Aslam Anis). Canadian Institute for Health Research. $80,156

Anis, A H, W Zhang, N Bansback, D P Guh, Z Amarsi, and C L Birmingham. “Obesity and overweight in Canada: an updated cost-of-illness study.” Obesity Reviews 11, no. 1 (2010): 31-40.
Anis, Aslam H, Nick Bansback, Sonia Sizto, Shiraz R Gupta, Mary K Willian, and Steve R Feldman. “Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.” The Journal of Dermatological Treatment In Press (2010).
Anis, Aslam H, Bohdan Nosyk, Huiying Sun, Daphne P Guh, Nick Bansback, Xin Li, Paul G Barnett, et al. “Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events.” Journal of Acquired Immune Deficiency Syndromes 51, no. 5 (August 15, 2009): 631-639. http://www.ncbi.nlm.nih.gov/pubmed/19430303.
Bansback, N. J., R. Ara, N. Barkham, A. Brennan, A. D. Fraser, P. Conway, A. Reynolds, and P. Emery. “Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.” Rheumatology 45, no. 8 (2006): 1029-1038.
Bansback, N. J., D. A. Regier, R. Ara, A. Brennan, K. Shojania, J. M. Esdaile, A. H. Anis, and C. A. Marra. “An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis: Focus on Tumour Necrosis Factor-[alpha] Antagonists.” Drugs 65, no. 4 (2005): 473-96.
Bansback, N., R. Ara, J. Karnon, and A. Anis. “Economic Evaluations in Rheumatoid Arthritis: A Critical Review of Measures Used to Define Health States.” PharmacoEconomics 26, no. 5 (2008): 395-408.
Bansback, N., A. Brennan, and A. H. Anis. “A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis.” Expert Review of Pharmacoeconomics and Outcomes Research 5, no. 5 (2005): 519-529.
Bansback, N., A. Brennan, and O. Ghatnekar. “The cost effectiveness of adalimumab in the treatment of moderate to severe rheumatoid arthritis patients in Sweden.” Annals of the Rheumatic Diseases 64, no. 7 (2005): 995-1002.
Bansback, N., C. Czoski-Murray, J. Carlton, G. Lewis, L. Hughes, M. Espallargues, C. Brand, and J. Brazier. “Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity.” Quality of Life Research 16, no. 3 (2007): 533-543.
Bansback, N., S. Davis, and J. Brazier. “Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.” Eye (2006).
Bansback, N., A. Maetzel, M. Drummond, A. Anis, C. Marra, P. Conway, M. Boers, P. Tugwell, and A. Boonen. “Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis.” Journal of Rheumatology 34, no. 5 (2007): 1178-83.
Bansback, N., C. Marra, A. Tsuchiya, A. Anis, D. Guh, T. Hammond, and J. Brazier. “Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis.” Arthritis Rheum 57, no. 6 (2007): 963-71.
Bansback, N., H. Sun, D. P. Guh, X. Li, B. Nosyk, S. Griffin, P. G. Barnett, and A. H. Anis. “Impact of the recall period on measuring health utilities for acute events.” Health Economics 17, no. 12 (2008): 1413-1419.
Bansback, N., S. Ward, and J. Karnon. “Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK.” The European Journal of Health Economics 5, no. 2 (2004): 188-189.
Bansback, N., A. Young, A. Brennan, and J. Dixey. “A prognostic model for functional outcome in early rheumatoid arthritis.” J Rheumatol 33, no. 8 (2006): 1503-10.
Bansback, NJ, J Brazier, A Tsuchiya, and A. Anis. “Using a discrete choice experiment to estimate societal health state utility values.” HEDS Discussion paper (2010).
Bansback, Nick, Roberta Ara, Sue Ward, Aslam Anis, and Hyon K Choi. “Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis.” PharmacoEconomics 27, no. 1 (2009): 25-37. http://www.ncbi.nlm.nih.gov/pubmed/19178122.
Bansback, Nick, Mark Harrison, John Brazier, Linda Davies, Jacek Kopec, Carlo Marra, Deborah Symmons, and Aslam Anis. “Health state utility values: A description of their development and application for rheumatic diseases.” Arthritis & Rheumatism 59, no. 7 (June 24, 2008): 1018-1026.
Bansback, Nick, Carlo A Marra, Axel Finckh, and Aslam Anis. “The economics of treatment in early rheumatoid arthritis.” Best Practice & Research Clinical Rheumatology 23, no. 1 (February 2009): 83-92. http://www.ncbi.nlm.nih.gov/pubmed/19233048.
Bansback, Nick, Sonia Sizto, Huiying Sun, Steven Feldman, Mary Kaye Willian, and Aslam Anis. “Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis.” Dermatology 219, no. 3 (2009): 209-218. http://www.ncbi.nlm.nih.gov/pubmed/19657180.
Bansback, Nick, and Carlo A Marra. “Now that we know what’s BeSt, what is good value for the money?” Arthritis & Rheumatism 61, no. 3 (March 15, 2009): 289-290. http://www.ncbi.nlm.nih.gov/pubmed/19248126.
Brennan, A., N. Bansback, R. Nixon, J. Madan, M. Harrison, K. Watson, and D. Symmons. “Modelling the cost effectiveness of TNF-{alpha} antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.” Rheumatology 46, no. 8 (2007): 1345-1354.
Brennan, A., N. Bansback, A. Reynolds, and P. Conway. “Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.” Rheumatology 43, no. 1 (2004): 62-72.
Espallargues, M., C. J. Czoski-Murray, N. J. Bansback, J. Carlton, G. M. Lewis, L. A. Hughes, C. S. Brand, and J. E. Brazier. “The Impact of Age-Related Macular Degeneration on Health Status Utility Values.” Investigative Ophthalmology & Visual Science 46, no. 11 (2005): 4016-4023.
Finckh, Axel, Nick Bansback, Carlo A Marra, Aslam H Anis, Kaleb Michaud, Stanley Lubin, Marc White, Sonia Sizto, and Matthew H Liang. “Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.” Annals of Internal Medicine 151, no. 9 (November 3, 2009): 612-621. http://www.ncbi.nlm.nih.gov/pubmed/19884622.
Guh, Daphne P, Wei Zhang, Nick Bansback, Zubin Amarsi, C Laird Birmingham, and Aslam H Anis. “The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis.” BMC Public Health 9 (2009): 88. http://www.ncbi.nlm.nih.gov/pubmed/19320986.
Harrison, M, L Davies, N Bansback, M McCoy, S Verstappen, K Watson, and D Symmons. “The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis.” Quality of Life Research 18, no. 9 (September 24, 2009): 1195-205. http://www.ncbi.nlm.nih.gov/pubmed/19777373.
Harrison, M. J., L. M. Davies, N. J. Bansback, M. Ingram, A. H. Anis, and D. P. Symmons. “The Validity and Responsiveness of Generic Utility Measures in Rheumatoid Arthritis: A Review.” Journal of Rheumatology 35, no. 4 (2008): 592-602.
Harrison, Mark J, Linda M Davies, Nick J Bansback, Melanie J McCoy, Tracey M Farragher, Suzanne M M Verstappen, Andrew Hassell, and Deborah P M Symmons. “Why do patients with inflammatory arthritis often score states ‘worse than death’ on the EQ-5D? An Investigation of the EQ-5D classification system.” Value in Health 12, no. 6 (September 2009): 1026-1034. http://www.ncbi.nlm.nih.gov/pubmed/19473335.
Harrison, Mark J, Mark Lunt, Suzanne M M Verstappen, Kath D Watson, Nick J Bansback, and Deborah P M Symmons. “Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis.” Health and Quality of Life Outcomes 11, no. 8 (2010): 21. http://www.ncbi.nlm.nih.gov/pubmed/20149253.
Jones, M. L., S. Hummel, N. Bansback, B. Orr, and M. Seymour. “A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for.” Health Technology Assessment 5, no. 25 (2001): 1-128.
Karnon, J, C Czoski-Murray, K Smith, C Brand, U Chakravarthy, S Davis, N Bansback, et al. “A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.” Health Technology Assessment 12, no. 27 (June 2008): 1-124. http://www.ncbi.nlm.nih.gov/pubmed/18513468.
Kopec, J A, E C Sayre, W M Flanagan, P Fines, J Cibere, Md M Rahman, N J Bansback, et al. “Development of a population-based microsimulation model of osteoarthritis in Canada.” Osteoarthritis and Cartilage / OARS, Osteoarthritis Research Society 18, no. 3 (October 23, 2009): 303-11. http://www.ncbi.nlm.nih.gov/pubmed/19879999.
Nixon, R. M., N. Bansback, and A. Brennan. “Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis.” Statistics in Medicine 26, no. 6 (2007): 1237-54.
Nixon, R., N. Bansback, and A. Brennan. “The efficacy of inhibiting tumour necrosis factor {alpha} and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.” Rheumatology 46, no. 7 (2007): 1140.
Nixon, Richard M, Nick Bansback, John W Stevens, Alan Brennan, and Jason Madan. “Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis.” Pharmaceutical Statistics 8, no. 2 (April–June 2009): 150-162. http://www.ncbi.nlm.nih.gov/pubmed/18942777.
Nixon, Richard M, Anthony O’Hagan, Jeremy Oakley, Jason Madan, John W Stevens, Nick Bansback, and Alan Brennan. “The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.” Pharmaceutical Statistics 8, no. 4 (April 1, 2009): 371-89. http://www.ncbi.nlm.nih.gov/pubmed/19340851.
Nosyk, Bohdan, Huiying Sun, Nick Bansback, Daphne P Guh, Xin Li, Paul Barnett, Ahmed Bayoumi, et al. “The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS.” Quality of Life Research 18, no. 7 (September 2009): 815-824. http://www.ncbi.nlm.nih.gov/pubmed/19562514.
Regier, D. A., N. Bansback, A. Dar Santos, and C. A. Marra. “Cost effectiveness of tumor necrosis factor-antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.” Expert Review of Pharmacoeconomics and Outcomes Research 7, no. 2 (2007): 155-169.
Sizto, S, N Bansback, S R Feldman, M K Willian, and A H Anis. “Economic evaluation of systemic therapies for moderate to severe psoriasis.” The British Journal of Dermatology 160, no. 6 (2009): 1264-72.
Thomas, K. C., B. Nosyk, C. G. Fisher, M. Dvorak, R. A. Patchell, W. F. Regine, A. Loblaw, N. Bansback, D. Guh, and H. Sun. “Cost-effectiveness of surgery plus radiotherapy versus radiotherapy alone for metastatic epidural spinal cord compression.” International Journal of Radiation Oncology, Biology, Physics 66, no. 4 (2006): 1212-1218.
Wailoo, A. J., N. Bansback, A. Brennan, K. Michaud, R. M. Nixon, and F. Wolfe. “Biologic Drugs for Rheumatoid Arthritis in the Medicare Program.” Arthritis & Rheumatism 58, no. 4 (2008): 939-946. http://www.cms.hhs.gov/reports/downloads/Wailoo.pdf.
Wailoo, A., N. Bansback, and J. Chilcott. “Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.” Rheumatology 47, no. 2 (2008): 119-120.
Ward, S., E. Morris, N. Bansback, N. Calvert, A. Crellin, D. Forman, and M. Larvin. “A rapid and systematic review of the clinical effectiveness and cost effectiveness of gemcitabine for the treatment of pancreatic cancer.” Health Technology Assessment 5, no. 24 (2001): 1-70.
Wong, Camilla L, Nick Bansback, Philip E Lee, and Aslam H Anis. “Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia.” The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques 36, no. 6 (November 2009): 735-739. http://www.ncbi.nlm.nih.gov/pubmed/19960752.
Zhang, Wei, Nick Bansback, Annelies Boonen, Adam Young, Amitabh Singh, and Aslam H Anis. “Validity of the work productivity and activity impairment questionnaire--general health version in patients with rheumatoid arthritis.” Arthritis Research & Therapy 12, no. 5 (2010): R177. http://www.ncbi.nlm.nih.gov/pubmed/20860837.
Zhang, Wei, Nick Bansback, Daphne Guh, Xin Li, Bohdan Nosyk, Carlo A Marra, and Aslam H Anis. “Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis.” The Journal of Rheumatology 35, no. 9 (September 2008): 1729-36. http://www.ncbi.nlm.nih.gov/pubmed/18688916.
Zhang, Wei, Nick Bansback, and Aslam H Anis. “Measuring and valuing productivity loss due to poor health: A critical review.” Social Science & Medicine 72, no. 2 (January 2011): 185-192. http://www.ncbi.nlm.nih.gov/pubmed/21146909.

“Visualizing Bayes’ theorem | Ramblings”, n.d. http://blog.oscarbonilla.com/2009/05/visualizing-bayes-theorem/.

“Visualizing Bayes’ theorem | Ramblings”, n.d. http://blog.oscarbonilla.com/2009/05/visualizing-bayes-theorem/.

“Visualizing Bayes’ theorem | Ramblings”, n.d. http://blog.oscarbonilla.com/2009/05/visualizing-bayes-theorem/.